Free Trial
NASDAQ:PROF

Profound Medical (PROF) Stock Price, News & Analysis

Profound Medical logo
$7.48 +0.04 (+0.54%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$7.49 +0.01 (+0.13%)
As of 02/21/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Profound Medical Stock (NASDAQ:PROF)

Key Stats

Today's Range
$7.40
$7.75
50-Day Range
$5.85
$7.90
52-Week Range
$5.63
$11.42
Volume
110,590 shs
Average Volume
96,602 shs
Market Capitalization
$224.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.25
Consensus Rating
Buy

Company Overview

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Profound Medical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

PROF MarketRank™: 

Profound Medical scored higher than 63% of companies evaluated by MarketBeat, and ranked 374th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Profound Medical has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Profound Medical has received no research coverage in the past 90 days.

  • Read more about Profound Medical's stock forecast and price target.
  • Earnings Growth

    Earnings for Profound Medical are expected to grow in the coming year, from ($1.12) to ($0.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Profound Medical is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Profound Medical is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Profound Medical has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Profound Medical's valuation and earnings.
  • Percentage of Shares Shorted

    1.15% of the outstanding shares of Profound Medical have been sold short.
  • Short Interest Ratio / Days to Cover

    Profound Medical has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Profound Medical has recently decreased by 9.68%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Profound Medical does not currently pay a dividend.

  • Dividend Growth

    Profound Medical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.15% of the outstanding shares of Profound Medical have been sold short.
  • Short Interest Ratio / Days to Cover

    Profound Medical has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Profound Medical has recently decreased by 9.68%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Profound Medical has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Profound Medical this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for PROF on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Profound Medical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.52% of the stock of Profound Medical is held by insiders.

  • Percentage Held by Institutions

    47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Profound Medical's insider trading history.
Receive PROF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter.

PROF Stock News Headlines

Raymond James Boosts Earnings Estimates for Profound Medical
Brokers Issue Forecasts for PROF Q1 Earnings
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
See More Headlines

PROF Stock Analysis - Frequently Asked Questions

Profound Medical's stock was trading at $7.51 on January 1st, 2025. Since then, PROF shares have decreased by 0.4% and is now trading at $7.48.
View the best growth stocks for 2025 here
.

Profound Medical Corp. (NASDAQ:PROF) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.05. The firm had revenue of $2.83 million for the quarter, compared to the consensus estimate of $3.30 million. Profound Medical had a negative net margin of 349.41% and a negative trailing twelve-month return on equity of 85.22%.

Top institutional investors of Profound Medical include FIL Ltd (5.98%), Gagnon Securities LLC (5.50%), Letko Brosseau & Associates Inc. (4.03%) and Timelo Investment Management Inc. (3.04%).

Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and DocuSign (DOCU).

Company Calendar

Last Earnings
11/07/2024
Today
2/22/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PROF
Employees
150
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.25
High Stock Price Target
$16.50
Low Stock Price Target
$12.00
Potential Upside/Downside
+90.5%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-28,570,000.00
Net Margins
-349.41%
Pretax Margin
-349.33%

Debt

Sales & Book Value

Annual Sales
$7.20 million
Book Value
$1.28 per share

Miscellaneous

Free Float
29,583,000
Market Cap
$224.70 million
Optionable
Optionable
Beta
0.88
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:PROF) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners